Aarti Pharmalabs PE ratio history and valuation
NSE: AARTIPHARMBSE: 543748Pharmaceuticals & BiotechnologySmall Cap
Aarti Pharmalabs Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2023
Last close ₹927.65up ₹45.70 (5.18%)BSE ₹927.55
Share price at the NSE close on 29 Oct 2026. Previous close ₹881.95.
29 Oct: open ₹900.00, high ₹970.00, low ₹855.00
52-week range of traded prices to 29 Oct 2026
₹585.00Low, 30 Mar 2026₹1,002.40High, 30 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹8,412 Cr705th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.38%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,82,34620.3% delivered
Aarti Pharmalabs' price to book, price to sales, EV to EBITDA and dividend yield on 29 Oct 2026, each against its own history of up to 5 years. Its P/E is not shown: the figures it needs for the twelve months to Sep 2026 are not complete or not comparable.
Aarti Pharmalabs PE ratio and valuation against its own history
- Price to earningsA results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to book3.73today
1 year
Median 3.20Today is at or above 90% of the 247 days
3 years
Median 3.20Today is at or above 81% of the 744 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.3.89today
1 year
Median 3.55Today is at or above 83% of the 247 days
3 years, since Feb 2024
Median 3.34Today is at or above 85% of the 675 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.18.95today
1 year
Median 16.97Today is at or above 79% of the 247 days
3 years, since Feb 2024
Median 16.26Today is at or above 90% of the 675 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.38%today
1 year
Median 0.58%Today is at or above 4% of the 247 days
3 years
Median 0.46%Today is at or above 25% of the 744 days
5 years, since Mar 2023
Median 0.44%Today is at or above 37% of the 887 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹2,255 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹2,161 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹836 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹23 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹487 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.9,06,79,813at 30 Sep 2026
Consolidated accounts, the twelve months to Sep 2026, ₹ crore.Aarti Pharmalabs financials ›
Aarti Pharmalabs valuation at each year end
On the last trading day of each March, the month the company's year ends.Aarti Pharmalabs dividend history
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 2,500 | 3,942 | 6,790 | 5,366 |
| Price to earnings | No results | 20.3 | 27.2 | 25.1 |
| Price to book | No results | 2.4 | 3.7 | 2.6 |
| Price to sales | No results | 2.2 | 3.3 | 3.0 |
| EV to EBITDA | No results | 11.8 | 16.3 | 14.1 |
| Dividend yield | 0.00% | 0.46% | 0.47% | 0.68% |
| Earnings yield | No results | 4.9% | 3.7% | 4.0% |
A ratio that does not exist on the day says why in its cell.
Aarti Pharmalabs market cap, since Mar 2023
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Book value and enterprise value
From the close on 29 Oct 2026.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹9,225 Cr
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹248.65
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- ₹3.50
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹5,076 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Aarti Pharmalabs is 46th among them by market cap. Each median leaves out Aarti Pharmalabs itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.3Across 158 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.1Across 143 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.48%Across 88 other companies
| Company | |||||
|---|---|---|---|---|---|
 Strides Pharma ScienceSTAR | 10,116 | 16.40 | 2.96 | 12.4 | 0.46% |
 Viyash ScientificVIYASH | 9,917 | – | 3.41 | 17.0 | 0.00% |
 Blue Jet HealthcareBLUEJET | 9,531 | 40.57 | – | – | 0.24% |
 Procter & Gamble HealthPGHL | 9,152 | 25.64 | 17.45 | 19.2 | 3.72% |
| Aarti PharmalabsAARTIPHARM | 8,412 | – | 3.73 | 19.0 | 0.38% |
 Symbiotec PharmalabSYMBIOTEC | 8,033 | – | – | – | 0.00% |
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,987 | 28.56 | 22.96 | 20.3 | 2.16% |
 Sanofi IndiaSANOFI | 7,346 | 20.15 | 8.89 | 13.7 | 3.86% |
 Bliss GVS PharmaBLISSGVS | 7,240 | 44.92 | 5.61 | 30.0 | 0.22% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.